Beginning with an overview of the endocannabinoid system (ECS) and the key cannabinoid receptors in the brain, she illustrates how the ECS regulates other neurotransmitters including dopamine, epinephrine and serotonin. Identifying Clinical Endocannabinoid Deficiency – a term first coined in 2003 - as an underlying cause of neurophysiological ailments including migraine headaches and fibromyalgia, Dr. Ross draws parallels to other neurotransmitter deficiencies that precipitate disease (like dopamine deficiency and Parkinson’s).
Dr. Ross explains how understanding this connection can help facilitate promising new therapeutic treatments using cannabis, outlining the specific mechanisms involved and the role cannabinoids play in treating conditions including ADHD, PTSD and depression.
She also discusses the risk factors and progression cycle of Alzheimer’s and Parkinson’s disease and how studies have shown that cannabis can bolster the ECS to slow the disease, highlighting its properties as an anti-aging, anti-inflammatory, neuroprotectant with the potential to restore cognitive function.
Dr. Ross’s presentation covers:
Directed toward the research, pharmaceutical, disease non-profit and medical communities, Dr. Ross lays out a visionary plan to expand the study, acceptance and implementation of cannabis as a viable, effective treatment for brain and neurological disorders.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly